Chiral will present the evidence we have that leronlimab is saving lives including results from the CSPs to the the Philippines FDA. Our partner in India will be doing the same. Either country might decide that benefit vs. no risk at all might be enough.

Where we'll start to be taken more seriously and might start cascading EUAs is after the Brazil critical interim results. There might be holdouts that want to see the full trial results in that but the dominoes should definitely start falling at the interim. I would expect countries that don't initially approve to get lined up to expedite production so that when full results are available they can actually get product.